EU court confirms €60m fine for Teva

Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Lilly mounts defence as generics circle Mounjaro and Zepbound

11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.

Pharma

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.

Pharma

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

6 August 2026 A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.

More features

Lilly mounts defence as generics circle Mounjaro and Zepbound

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

Kirkland clears conflicts hurdle in trade secrets spat

Former senior attorney-advisor to ITC commissioners joins Mintz

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

K&L Gates expands European practice with Munich team hire

EU court confirms €60m fine for Teva

More on this story

Editor's picks

Editor's picks

More features